PlusNews Reports On Importance Of Cost-Effectiveness Of ZAMSTAR Study For Policymakers, Donors Amid Economic Downturn

PlusNews reports on the results of the Zambia-South Africa TB and AIDS Reduction (ZAMSTAR) study released on Monday at the International Lung Health Conference in Lille, France, which show that “[h]ome-based tuberculosis (TB) education and testing reduced community TB prevalence by about 20 percent.” Noting that “the trial cost US$27 million [and] the interventions it piloted cost about $0.80 per patient,” the news service writes that while “the cost-effectiveness of household outreach has not yet been calculated, … [t]his will be of particular interest not only to national policymakers but also donors, who continue to tighten purse strings amid a global economic downturn” (11/1).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.